JP4155711B2 - ヘパリン結合能の亢進したポリペプチド変異体 - Google Patents
ヘパリン結合能の亢進したポリペプチド変異体 Download PDFInfo
- Publication number
- JP4155711B2 JP4155711B2 JP2000598634A JP2000598634A JP4155711B2 JP 4155711 B2 JP4155711 B2 JP 4155711B2 JP 2000598634 A JP2000598634 A JP 2000598634A JP 2000598634 A JP2000598634 A JP 2000598634A JP 4155711 B2 JP4155711 B2 JP 4155711B2
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- acid sequence
- nucleic acid
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 179
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 178
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 176
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229920000669 heparin Polymers 0.000 title claims abstract description 46
- 229960002897 heparin Drugs 0.000 title claims abstract description 46
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 44
- 150000001413 amino acids Chemical class 0.000 claims abstract description 37
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 35
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 35
- 230000011164 ossification Effects 0.000 claims abstract description 34
- 238000006467 substitution reaction Methods 0.000 claims abstract description 8
- 238000003780 insertion Methods 0.000 claims abstract description 7
- 230000037431 insertion Effects 0.000 claims abstract description 7
- 230000029663 wound healing Effects 0.000 claims abstract description 5
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 51
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 36
- 102000015636 Oligopeptides Human genes 0.000 claims description 29
- 108010038807 Oligopeptides Proteins 0.000 claims description 29
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 26
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 26
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 26
- 235000001014 amino acid Nutrition 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
- 230000002138 osteoinductive effect Effects 0.000 claims description 17
- 102000005962 receptors Human genes 0.000 claims description 17
- 108020003175 receptors Proteins 0.000 claims description 17
- 239000000758 substrate Substances 0.000 claims description 17
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 13
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 13
- 235000018417 cysteine Nutrition 0.000 claims description 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 10
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 238000007792 addition Methods 0.000 claims description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 7
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 238000010367 cloning Methods 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 210000004897 n-terminal region Anatomy 0.000 claims description 5
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 3
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 3
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 3
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 3
- 238000002703 mutagenesis Methods 0.000 claims description 3
- 231100000350 mutagenesis Toxicity 0.000 claims description 3
- 230000004819 osteoinduction Effects 0.000 claims description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 3
- 229920001059 synthetic polymer Polymers 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 2
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 238000001308 synthesis method Methods 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 239000002628 heparin derivative Substances 0.000 claims 4
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 29
- 230000001965 increasing effect Effects 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 8
- 230000022159 cartilage development Effects 0.000 abstract description 6
- 230000000638 stimulation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 47
- 235000018102 proteins Nutrition 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 44
- 210000000988 bone and bone Anatomy 0.000 description 35
- 239000003102 growth factor Substances 0.000 description 21
- 230000004071 biological effect Effects 0.000 description 20
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 17
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 17
- 229940112869 bone morphogenetic protein Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 108010059616 Activins Proteins 0.000 description 12
- 239000000488 activin Substances 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 102100026818 Inhibin beta E chain Human genes 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 108010004250 Inhibins Proteins 0.000 description 9
- 102000002746 Inhibins Human genes 0.000 description 9
- 239000000893 inhibin Substances 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 8
- 102000014429 Insulin-like growth factor Human genes 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 210000002805 bone matrix Anatomy 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 7
- 102000003982 Parathyroid hormone Human genes 0.000 description 7
- 108090000445 Parathyroid hormone Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 239000000199 parathyroid hormone Substances 0.000 description 7
- 229960001319 parathyroid hormone Drugs 0.000 description 7
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 6
- 108010067787 Proteoglycans Proteins 0.000 description 6
- 102000016611 Proteoglycans Human genes 0.000 description 6
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 6
- 210000000845 cartilage Anatomy 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 5
- 210000003837 chick embryo Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000008108 Osteoprotegerin Human genes 0.000 description 4
- 108010035042 Osteoprotegerin Proteins 0.000 description 4
- 108010025832 RANK Ligand Proteins 0.000 description 4
- 102000043168 TGF-beta family Human genes 0.000 description 4
- 108091085018 TGF-beta family Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 235000014304 histidine Nutrition 0.000 description 4
- 102000045896 human BMP2 Human genes 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 4
- 230000002188 osteogenic effect Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 3
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000000982 limb bud Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000030016 Avascular necrosis Diseases 0.000 description 2
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 2
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010031264 Osteonecrosis Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000006877 Pituitary Hormones Human genes 0.000 description 2
- 108010047386 Pituitary Hormones Proteins 0.000 description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000002648 chondrogenic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000002710 gonadal effect Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 239000000960 hypophysis hormone Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- RVCKCEDKBVEEHL-UHFFFAOYSA-N 2,3,4,5,6-pentachlorobenzyl alcohol Chemical compound OCC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl RVCKCEDKBVEEHL-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000018918 Activin Receptors Human genes 0.000 description 1
- 108010052946 Activin Receptors Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- -1 BMP-12 Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 101710117973 Bone morphogenetic protein 8A Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 102100035418 Ceramide synthase 4 Human genes 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 description 1
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 1
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000737544 Homo sapiens Ceramide synthase 4 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- JHKXZYLNVJRAAJ-WDSKDSINSA-N Met-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(O)=O JHKXZYLNVJRAAJ-WDSKDSINSA-N 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- 101100165554 Mus musculus Bmp5 gene Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000007453 TGF-beta Superfamily Proteins Human genes 0.000 description 1
- 108010085004 TGF-beta Superfamily Proteins Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241001447056 Uristes Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 1
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001707 blastogenic effect Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 102000006533 chordin Human genes 0.000 description 1
- 108010008846 chordin Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000035194 endochondral ossification Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 230000029795 kidney development Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002265 redox agent Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000006128 skin development Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906096A DE19906096A1 (de) | 1999-02-13 | 1999-02-13 | Protein mit einem Heparin-bindenden Epitop |
| DE19906096.7 | 1999-02-13 | ||
| PCT/EP2000/000637 WO2000047736A1 (de) | 1999-02-13 | 2000-01-27 | Polypeptidvarianten mit erhöhter heparin-bindungsfähigkeit |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007258333A Division JP2008086319A (ja) | 1999-02-13 | 2007-10-02 | ヘパリン結合能の亢進したポリペプチド変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002536016A JP2002536016A (ja) | 2002-10-29 |
| JP2002536016A5 JP2002536016A5 (enExample) | 2007-11-22 |
| JP4155711B2 true JP4155711B2 (ja) | 2008-09-24 |
Family
ID=7897433
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000598634A Expired - Fee Related JP4155711B2 (ja) | 1999-02-13 | 2000-01-27 | ヘパリン結合能の亢進したポリペプチド変異体 |
| JP2007258333A Pending JP2008086319A (ja) | 1999-02-13 | 2007-10-02 | ヘパリン結合能の亢進したポリペプチド変異体 |
| JP2008201668A Pending JP2009011323A (ja) | 1999-02-13 | 2008-08-05 | ヘパリン結合能の亢進したポリペプチド変異体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007258333A Pending JP2008086319A (ja) | 1999-02-13 | 2007-10-02 | ヘパリン結合能の亢進したポリペプチド変異体 |
| JP2008201668A Pending JP2009011323A (ja) | 1999-02-13 | 2008-08-05 | ヘパリン結合能の亢進したポリペプチド変異体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7253254B1 (enExample) |
| EP (1) | EP1151095B1 (enExample) |
| JP (3) | JP4155711B2 (enExample) |
| CN (1) | CN1169959C (enExample) |
| AT (1) | ATE470713T1 (enExample) |
| AU (1) | AU762387B2 (enExample) |
| BR (1) | BR0008785A (enExample) |
| CA (1) | CA2362496C (enExample) |
| DE (2) | DE19906096A1 (enExample) |
| RU (1) | RU2227743C2 (enExample) |
| WO (1) | WO2000047736A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734525B2 (en) | 2003-12-31 | 2014-05-27 | Warsaw Orthopedic, Inc. | Osteoinductive demineralized cancellous bone |
| WO2005065396A2 (en) | 2003-12-31 | 2005-07-21 | Osteotech, Inc. | Improved bone matrix compositions and methods |
| DE602005023714D1 (de) * | 2004-02-20 | 2010-11-04 | Biosurface Eng Tech Inc | Positiver modulator des knochenmorphogenetisches protein-2 (bmp-2) |
| EP1885751B1 (en) * | 2005-05-27 | 2011-11-16 | BBS - Bioactive Bone Substitutes Oy | Bone morphogenetic protein 6 containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof |
| US9216212B2 (en) * | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US8992965B2 (en) | 2005-11-01 | 2015-03-31 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| JP2007332106A (ja) * | 2006-06-16 | 2007-12-27 | Okayama Univ | 骨形成用徐放性医薬組成物 |
| CA2692240C (en) | 2006-06-22 | 2018-03-13 | Biosurface Engineering Technologies, Inc. | Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis |
| US20080206299A1 (en) * | 2007-02-27 | 2008-08-28 | Shimp Lawrence A | Method for Recovering Minerals From Bone and Use of Same |
| AU2008265850B2 (en) | 2007-06-15 | 2014-06-26 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| US9554920B2 (en) | 2007-06-15 | 2017-01-31 | Warsaw Orthopedic, Inc. | Bone matrix compositions having nanoscale textured surfaces |
| WO2009009688A1 (en) | 2007-07-10 | 2009-01-15 | Osteotech, Inc. | Delivery system |
| JP2009045142A (ja) * | 2007-08-16 | 2009-03-05 | Okayama Univ | 生体内にて基材周囲に骨形成を誘導するための基材処理方法 |
| WO2010039224A2 (en) | 2008-09-30 | 2010-04-08 | University Of Massachusetts Medical School | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines |
| JP5799409B2 (ja) * | 2008-12-19 | 2015-10-28 | 国立大学法人 新潟大学 | ヘパリン親和性エリスロポエチン |
| US9101475B2 (en) | 2009-02-12 | 2015-08-11 | Warsaw Orthopedic, Inc. | Segmented delivery system |
| GB201601136D0 (en) | 2016-01-21 | 2016-03-09 | Mörgelin Matthias And Abdillahi Suado M | Novel polypeptides and medical uses thereof |
| JP6629488B2 (ja) | 2016-12-30 | 2020-01-15 | バイオジェンド セラピューティクス カンパニー リミテッド | 組換えポリペプチド、核酸分子、それらを含む組成物及びそれらの製造、使用方法 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4455256A (en) | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| US4804744A (en) | 1984-01-04 | 1989-02-14 | International Genetic Engineering, Inc. | Osteogenic factors |
| NZ210699A (en) | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
| US4627982A (en) | 1984-07-16 | 1986-12-09 | Collagen Corporation | Partially purified bone-inducing factor |
| US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
| ZA874681B (en) | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
| US5366875A (en) | 1986-07-01 | 1994-11-22 | Genetics Institute, Inc. | Methods for producing BMP-7 proteins |
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| US5106748A (en) | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| US4877864A (en) | 1987-03-26 | 1989-10-31 | Genetics Institute, Inc. | Osteoinductive factors |
| US5631142A (en) | 1986-07-01 | 1997-05-20 | Genetics Institute, Inc. | Compositions comprising bone morphogenetic protein-2 (BMP-2) |
| US5459047A (en) | 1986-07-01 | 1995-10-17 | Genetics Institute, Inc. | BMP-6 proteins |
| US5250302A (en) | 1988-04-08 | 1993-10-05 | Stryker Corporation | Osteogenic devices |
| US5324819A (en) | 1988-04-08 | 1994-06-28 | Stryker Corporation | Osteogenic proteins |
| US4968590A (en) | 1988-04-08 | 1990-11-06 | Stryker Corporation | Osteogenic proteins and polypeptides |
| US5354557A (en) | 1988-04-08 | 1994-10-11 | Stryker Corporation | Osteogenic devices |
| US5344654A (en) | 1988-04-08 | 1994-09-06 | Stryker Corporation | Prosthetic devices having enhanced osteogenic properties |
| EP1225225A3 (en) | 1988-04-08 | 2003-01-08 | Stryker Corporation | Osteogenic devices |
| US5011691A (en) | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US4975526A (en) | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
| US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5258494A (en) | 1988-04-08 | 1993-11-02 | Stryker Corporation | Osteogenic proteins |
| US4967737A (en) | 1988-08-03 | 1990-11-06 | Osteg Dyne Inc. | Method and device for treating bone disorders characterized by low bone mass |
| US5106626A (en) | 1988-10-11 | 1992-04-21 | International Genetic Engineering, Inc. | Osteogenic factors |
| US5510418A (en) | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
| US4928959A (en) | 1988-12-16 | 1990-05-29 | Osteo-Dyne, Inc. | Method and device for providing active exercise treatment for a patient suffering from a bone disorder |
| EP0384731B1 (en) | 1989-02-23 | 1996-12-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Osteogenic growth polypeptides identified from regenerating bone marrow |
| WO1990010694A1 (fr) * | 1989-03-06 | 1990-09-20 | Suntory Limited | Nouvelle superoxyde dismutase |
| DK0429570T3 (da) | 1989-03-28 | 1998-04-27 | Genetics Inst | Osteoinducerende præparater |
| US5061786A (en) | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
| CA2020729A1 (en) | 1989-07-19 | 1991-01-20 | Michael C. Kiefer | Bone morphogenetic protein |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| CA2024629C (en) | 1989-09-06 | 2001-07-24 | Taiheiyo Cement Corporation | Xenopus laevis bone morphogenic protein, dna encoding same and use thereof |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| CA2042577A1 (en) | 1989-10-17 | 1991-04-18 | Hermann Oppermann | Osteogenic devices |
| GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| DE69132823T2 (de) | 1990-05-16 | 2002-07-18 | Genetics Institute, Inc. | Knochen- und knorpel-bildung hervorrufende proteine |
| US5168050A (en) | 1990-05-24 | 1992-12-01 | Genentech, Inc. | Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion |
| US5645591A (en) | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
| US5364839A (en) | 1990-06-18 | 1994-11-15 | Genetics Institute, Inc. | Osteoinductive pharmaceutical formulations |
| DK0643767T3 (da) | 1990-10-18 | 1999-04-26 | Stryker Corp | Osteogene peptider |
| CA2071912C (en) | 1990-11-30 | 2002-10-15 | Hanne Bentz | Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair |
| US5652118A (en) | 1991-03-11 | 1997-07-29 | Creative Biomolecules, Inc. | Nucleic acid encoding a novel morphogenic protein, OP-3 |
| US6395883B1 (en) | 1991-03-11 | 2002-05-28 | Curis, Inc. | Soluble morphogenic protein complex compositions of matter |
| DE69231946T2 (de) | 1991-03-11 | 2002-04-04 | Curis, Inc. | Protein-induzierende morphogenese |
| US5318898A (en) | 1991-04-02 | 1994-06-07 | Genetics Institute, Inc. | Production of recombinant bone-inducing proteins |
| MX9203083A (es) | 1991-06-21 | 1994-08-31 | Genetics Inst | Formulaciones farmaceuticas de proteinas osteogenicas. |
| KR100259827B1 (ko) | 1991-11-04 | 2000-06-15 | 브루스 엠. 에이센, 토마스 제이 데스로저 | 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법 |
| PT625989E (pt) | 1992-02-12 | 2000-06-30 | Bioph Biotech Entw Pharm Gmbh | Sequencias de adn que codificam novos factores de crescimento/diferenciacao |
| US6120760A (en) | 1992-02-12 | 2000-09-19 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung | Growth/differentiation factors of the TGF-β family |
| US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| EP1439190A1 (en) | 1993-01-12 | 2004-07-21 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-5 |
| IL104954A (en) | 1993-03-04 | 2006-08-01 | Yissum Res Dev Co | Use of osteogenic oligopeptides in the preparation of pharmaceutical compositions for the treatment of bone diseases and some such novel oligopeptides, pharmaceutical compositions containing them and their preparation |
| US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
| IL108947A0 (en) | 1993-03-12 | 1994-06-24 | Osteopharm Ltd | Bone stimulating factor |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US5637480A (en) | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
| EP0804214A4 (en) | 1993-07-09 | 1998-05-20 | Univ Johns Hopkins Med | FACTOR 6 OF CELL GROWTH AND DIFFERENTIATION |
| IL110589A0 (en) | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
| US5385887A (en) | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US5399677A (en) | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| TW440566B (en) | 1994-07-25 | 2001-06-16 | Novartis Ag | Novel process for the production of biologically active dimeric protein |
| US6180606B1 (en) | 1994-09-28 | 2001-01-30 | Gensci Orthobiologics, Inc. | Compositions with enhanced osteogenic potential, methods for making the same and uses thereof |
| US5707962A (en) | 1994-09-28 | 1998-01-13 | Gensci Regeneration Sciences Inc. | Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof |
| US5782919A (en) | 1995-03-27 | 1998-07-21 | Sdgi Holdings, Inc. | Interbody fusion device and method for restoration of normal spinal anatomy |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5800811A (en) * | 1995-06-06 | 1998-09-01 | Hall; Frederick L. | Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site |
| US5902785A (en) | 1995-06-06 | 1999-05-11 | Genetics Institute, Inc. | Cartilage induction by bone morphogenetic proteins |
| ZA966489B (en) | 1995-08-03 | 1997-02-26 | Bioph Biotech Entw Pharm Gmbh | New protein human MP52 Arg. |
| DE19548476A1 (de) * | 1995-12-22 | 1997-06-26 | Bioph Biotech Entw Pharm Gmbh | Zielgerichtete Verbindungen mit knorpel- und/oder knocheninduzierender Aktivität |
| JP2000506375A (ja) | 1996-01-26 | 2000-05-30 | エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ | アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用 |
| US5877153A (en) * | 1996-06-11 | 1999-03-02 | Commonwealth Biotechnologies Inc. | Heparin-binding peptides |
| EP0959682B1 (en) | 1996-10-08 | 2007-11-28 | University of Washington | Therapeutic applications of laminin and laminin-derived protein fragments |
| US6080779A (en) | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
| US6894022B1 (en) * | 1998-08-27 | 2005-05-17 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
| AU2001251507A1 (en) | 2000-04-11 | 2001-10-23 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
-
1999
- 1999-02-13 DE DE19906096A patent/DE19906096A1/de not_active Ceased
-
2000
- 2000-01-27 EP EP00901137A patent/EP1151095B1/de not_active Expired - Lifetime
- 2000-01-27 CN CNB008037183A patent/CN1169959C/zh not_active Expired - Fee Related
- 2000-01-27 WO PCT/EP2000/000637 patent/WO2000047736A1/de not_active Ceased
- 2000-01-27 RU RU2001123926/15A patent/RU2227743C2/ru not_active IP Right Cessation
- 2000-01-27 DE DE50015938T patent/DE50015938D1/de not_active Expired - Lifetime
- 2000-01-27 AT AT00901137T patent/ATE470713T1/de not_active IP Right Cessation
- 2000-01-27 AU AU21106/00A patent/AU762387B2/en not_active Ceased
- 2000-01-27 JP JP2000598634A patent/JP4155711B2/ja not_active Expired - Fee Related
- 2000-01-27 CA CA2362496A patent/CA2362496C/en not_active Expired - Fee Related
- 2000-01-27 US US09/913,467 patent/US7253254B1/en not_active Expired - Fee Related
- 2000-01-27 BR BR0008785-8A patent/BR0008785A/pt not_active Application Discontinuation
-
2007
- 2007-10-02 JP JP2007258333A patent/JP2008086319A/ja active Pending
-
2008
- 2008-08-05 JP JP2008201668A patent/JP2009011323A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2362496A1 (en) | 2000-08-17 |
| AU2110600A (en) | 2000-08-29 |
| DE19906096A1 (de) | 2000-08-17 |
| JP2002536016A (ja) | 2002-10-29 |
| JP2009011323A (ja) | 2009-01-22 |
| EP1151095B1 (de) | 2010-06-09 |
| BR0008785A (pt) | 2001-11-06 |
| EP1151095A1 (de) | 2001-11-07 |
| JP2008086319A (ja) | 2008-04-17 |
| RU2227743C2 (ru) | 2004-04-27 |
| CA2362496C (en) | 2011-04-19 |
| CN1340102A (zh) | 2002-03-13 |
| AU762387B2 (en) | 2003-06-26 |
| US7253254B1 (en) | 2007-08-07 |
| WO2000047736A1 (de) | 2000-08-17 |
| DE50015938D1 (de) | 2010-07-22 |
| CN1169959C (zh) | 2004-10-06 |
| ATE470713T1 (de) | 2010-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008086319A (ja) | ヘパリン結合能の亢進したポリペプチド変異体 | |
| US5986056A (en) | Chordin compositions | |
| CA2265508C (en) | Bone morphogenetic protein-16 (bmp-16) compositions | |
| JP3706133B2 (ja) | Ｂｍｐ−９組成物 | |
| JP3681069B2 (ja) | Ｂｍｐ−１１組成物 | |
| US6352972B1 (en) | Bone morphogenetic proteins and their use in bone growth | |
| US7151086B2 (en) | Bone morphogenetic protein (BMP)-17 and BMP-18 compositions | |
| KR19990014917A (ko) | Bmp-15 조성물 | |
| US9200048B2 (en) | High activity growth factor mutants | |
| CN1088616A (zh) | 大潜在转化生长因子-β复合物及其有用结构物的生产方法 | |
| KR102067724B1 (ko) | 연골 형성을 유도하기 위한 gdf-5 돌연변이체 | |
| EP1591526B1 (en) | Frazzled nucleotide sequences, expression products, compositions and uses | |
| JP2008538073A (ja) | 改善された生物学的活性を有する成長因子突然変異体 | |
| CA2574929C (en) | Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions | |
| AU763300B2 (en) | Bone morphogenetic protein-16 (BMP-16) compositions | |
| KR20190005240A (ko) | Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드를 포함하는 골 및 연골 질환 치료용 조성물 및 그의 이용 | |
| MXPA00005709A (en) | Bone morphogenetic protein (bmp)-17 and bmp-18 compositions | |
| HK1230218A1 (en) | Protein substance having triple helix structure and manufacturing method therefor | |
| HK1230218A (en) | Protein substance having triple helix structure and manufacturing method therefor | |
| KR20070072938A (ko) | 골유도 단백질 및 펩티드의 세포간 전달방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040507 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040806 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040813 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041105 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050523 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20061020 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20061020 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070803 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071002 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20071002 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20071015 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080331 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080415 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080702 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080708 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110718 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110718 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120718 Year of fee payment: 4 |
|
| LAPS | Cancellation because of no payment of annual fees |